These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 21734353)

  • 41. Impact of viral amino acid substitutions and host interleukin-28b polymorphism on replication and susceptibility to interferon of hepatitis C virus.
    Hiraga N; Abe H; Imamura M; Tsuge M; Takahashi S; Hayes CN; Ochi H; Tateno C; Yoshizato K; Nakamura Y; Kamatani N; Chayama K
    Hepatology; 2011 Sep; 54(3):764-71. PubMed ID: 21618576
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Mutations in E2-PePHD, NS5A-PKRBD, NS5A-ISDR, and NS5A-V3 of hepatitis C virus genotype 1 and their relationships to pegylated interferon-ribavirin treatment responses.
    Muñoz de Rueda P; Casado J; Patón R; Quintero D; Palacios A; Gila A; Quiles R; León J; Ruiz-Extremera A; Salmerón J
    J Virol; 2008 Jul; 82(13):6644-53. PubMed ID: 18448540
    [TBL] [Abstract][Full Text] [Related]  

  • 43. High ability to predict the treatment outcome of peginterferon and ribavirin combination therapy based on the reduction in HCV RNA levels at 4 weeks after starting therapy and amino acid substitutions in the hepatitis C virus in patients infected with HCV genotype 1b.
    Toyoda H; Kumada T; Kiriyama S; Tanikawa M; Hisanaga Y; Kanamori A; Tada T; Arakawa T; Fujimori M; Niinomi T; Ando N; Yasuda S; Sakai K; Kimura J
    J Gastroenterol; 2011 Apr; 46(4):501-9. PubMed ID: 20927636
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b.
    Akuta N; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2007 Nov; 79(11):1686-95. PubMed ID: 17854035
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Predictive values of amino acid sequences of the core and NS5A regions in antiviral therapy for hepatitis C: a Japanese multi-center study.
    Okanoue T; Itoh Y; Hashimoto H; Yasui K; Minami M; Takehara T; Tanaka E; Onji M; Toyota J; Chayama K; Yoshioka K; Izumi N; Akuta N; Kumada H
    J Gastroenterol; 2009; 44(9):952-63. PubMed ID: 19517057
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Association of IL28B genotype and viral response of hepatitis C virus genotype 2 to interferon plus ribavirin combination therapy.
    Akuta N; Suzuki F; Seko Y; Kawamura Y; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2012 Oct; 84(10):1593-9. PubMed ID: 22930507
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Reappraisal of the importance of mutations in the NS5A-PKR-binding domain of hepatitis C-1b virus in the era of optimally individualized therapy.
    Chen TM; Huang PT; Wen CF; Tung JN; Chow KC; Chen YP
    J Viral Hepat; 2011 Feb; 18(2):119-28. PubMed ID: 20236237
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Anti HCV drugs--ribavirin, telaprevir].
    Sakamoto M; Enomoto N
    Nihon Rinsho; 2012 Apr; 70(4):614-9. PubMed ID: 22568142
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Impact of genetic polymorphisms near the IL28B gene and amino acid substitutions in the hepatitis C virus core region on interferon sensitivity/resistance in patients with chronic hepatitis C.
    Toyoda H; Kumada T; Tada T; Kawaguchi T; Murakami Y; Matsuda F
    J Med Virol; 2011 Jul; 83(7):1203-11. PubMed ID: 21567424
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Mutations in the NS5A and E2-PePHD regions of hepatitis C virus genotype 1b and response to combination therapy of interferon plus ribavirin.
    Yang SS; Lai MY; Chen DS; Chen GH; Kao JH
    Liver Int; 2003 Dec; 23(6):426-33. PubMed ID: 14986817
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Response to combination therapy of HCV 3a infected Pakistani patients and the role of NS5A protein.
    Ali I; Khan S; Attaullah S; Khan SN; Khan J; Siraj S; Iqbal A; Swati ZA; Idrees M
    Virol J; 2011 May; 8():258. PubMed ID: 21609495
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Longitudinal analysis of the 5'UTR, E2-PePHD and NS5A-PKRBD genomic regions of hepatitis C virus genotype 1a in association with the response to peginterferon and ribavirin therapy in HIV-coinfected patients.
    Bolcic F; Laufer N; Torres C; Cassino L; Reynoso R; Quarleri J
    Antiviral Res; 2012 Aug; 95(2):72-81. PubMed ID: 22683884
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Mutations in the NS5A and E2-PePHD region of hepatitis C virus type 1b and correlation with the response to combination therapy with interferon and ribavirin.
    Hung CH; Lee CM; Lu SN; Lee JF; Wang JH; Tung HD; Chen TM; Hu TH; Chen WJ; Changchien CS
    J Viral Hepat; 2003 Mar; 10(2):87-94. PubMed ID: 12614464
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Core mutations, IL28B polymorphisms and response to peginterferon/ribavirin treatment in Swedish patients with hepatitis C virus genotype 1 infection.
    Alestig E; Arnholm B; Eilard A; Lagging M; Nilsson S; Norkrans G; Wahlberg T; Wejstål R; Westin J; Lindh M
    BMC Infect Dis; 2011 May; 11():124. PubMed ID: 21569441
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prediction of response to peginterferon-alfa-2b plus ribavirin therapy in Japanese patients infected with hepatitis C virus genotype 1b.
    Hashimoto Y; Ochi H; Abe H; Hayashida Y; Tsuge M; Mitsui F; Hiraga N; Imamura M; Takahashi S; Nelson Hayes C; Ohishi W; Kubo M; Tsunoda T; Kamatani N; Nakamura Y; Chayama K
    J Med Virol; 2011 Jun; 83(6):981-8. PubMed ID: 21503910
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Amino acid substitutions in the hepatitis C virus core region of genotype 1b are the important predictor of severe insulin resistance in patients without cirrhosis and diabetes mellitus.
    Akuta N; Suzuki F; Hirakawa M; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2009 Jun; 81(6):1032-9. PubMed ID: 19382270
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Low-dose pegylated interferon-α2a plus ribavirin therapy for elderly and/or cirrhotic patients with HCV genotype-1b and high viral load.
    Tamai H; Mori Y; Shingaki N; Kawashima A; Tsukuda H; Higashi K; Moribata K; Kawaguchi M; Ueda K; Deguchi H; Inoue I; Maekita T; Iguchi M; Kato J; Ichinose M
    Antivir Ther; 2014; 19(1):107-15. PubMed ID: 24162072
    [TBL] [Abstract][Full Text] [Related]  

  • 58. IL28B polymorphism may guide pegylated interferon plus ribavirin therapy even after curative treatment for hepatitis C virus-related hepatocellular carcinoma.
    Kawaoka T; Aikata H; Takaki S; Hiramatsu A; Waki K; Hiraga N; Miki D; Tsuge M; Imamura M; Kawakami Y; Takahashi S; Ochi H; Tashiro H; Ohdan H; Chayama K
    J Viral Hepat; 2011 Oct; 18(10):e550-60. PubMed ID: 21914076
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Does sequencing the PKRBD of hepatitis C virus NS5A predict therapeutic response to combination therapy in an Australian population?
    Macquillan GC; Niu X; Speers D; English S; Garas G; Harnett GB; Reed WD; Allan JE; Jeffrey GP
    J Gastroenterol Hepatol; 2004 May; 19(5):551-7. PubMed ID: 15086599
    [TBL] [Abstract][Full Text] [Related]  

  • 60. IL28B polymorphism genotyping as predictor of rapid virologic response during interferon plus ribavirin treatment in hepatitis C virus genotype 1 patients.
    Rosso C; Abate ML; Ciancio A; Strona S; Caviglia GP; Olivero A; Touscoz GA; Rizzetto M; Pellicano R; Smedile A
    World J Gastroenterol; 2014 Sep; 20(36):13146-52. PubMed ID: 25278709
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.